Novartis Phase 3 cancer drug Panobinostat may correct Niemann Pick Type C cholesterol defect through inhibiting histone deacetylase (HDAC)

March 21, 2011 by Chris Hempel
Filed under Featured Stories

I almost fell off my chair a few minutes ago. I just posted a blog on news from Notre Dame and Cornell about HDAC inhibitors correcting the Niemann Pick Type C defect in cell culture. I just read on PNAS that the Novartis cancer drug Panobinostat (LBH-589), a Phase 3 drug developed for the treatment […]

Tags: Alzheimers, cancer drug, cholesterol homeostasis, Cornell, Gleevec, HDAC inhibitor treatment, HDAC inhibitors, HDAC1, HDAC2, HDIs, histone deacetylase (HDAC) enzymes, Histone deacetylase inhibitor, LBH-589, neurodegenerative, Niemann Pick Type C, Notre Dame, Novartris, NPC phenotype, NPC1, NPC1I1061T protein, NPC2, oral HDAC inhibitor, Panobinostat, Paul Greengard, small molecule histone deacetylase (HDAC) inhibitors

The Addi and Cassi Fund - Niemann Pick Type C

Novartis Phase 3 cancer drug Panobinostat may correct Niemann Pick Type C cholesterol defect through inhibiting histone deacetylase (HDAC)

CNN – Dr. Sanjay Gupta Follows Addi & Cassi for 4 Years

Join our Mailing List!

Resources

Blogroll

Admin